Search research articles
Contact Us
Filters
Showing results (171-180 of 248) with videos related to
Page
of 25
Sort By:
Frontiers in Physiology
|
March 9, 2026
An evidence-based multi-factorial model to predict the oxygen cost of ventilation during ramp-incremental cycle ergometry exercise
Bridgette G J O'Malley, Robert A Robergs, Karel Hrach, et al.
Annals of Plastic Surgery
|
June 2, 2011
Outcome study of the surgical management of panniculitis
John Zannis, Benjamin C Wood, Leah P Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 1999
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models
M G Rosenblum, L K Shawver, J W Marks, et al.
Cancer Research
|
November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies
Yu Cao, James D Marks, John W Marks, et al.
Oncogene
|
February 5, 2013
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies
Y Cao, J W Marks, Z Liu, et al.
The American Journal of Gastroenterology
|
February 1, 1978
Gallstone dissolution by chenodeoxycholic acid and phenobarbital
J W Marks, J H Sherman, G G Bonorris, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
June 29, 1999
The spontaneous coat color mutant white nose (wn) maps to murine chromosome 15
P W Marks, J L Bandura, D B Shieh, et al.
Gastroenterology
|
August 1, 1984
Cyclic nucleotides and glycoproteins during formation of cholesterol gallstones in prairie dogs
R A Zak, P G Frenkiel, J W Marks, et al.
Molecular Cancer Therapeutics
|
March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu
Yu Cao, Khalid A Mohamedali, John W Marks, et al.
Vaccine
|
April 4, 2022
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years
Patrick R Funk, Osman N Yogurtcu, Richard A Forshee, et al.
Page
of 25
Search research articles
Search
Showing results (171-180 of 248) with videos related to
Sort By:
Page
of 25
Frontiers in Physiology
|
March 9, 2026
An evidence-based multi-factorial model to predict the oxygen cost of ventilation during ramp-incremental cycle ergometry exercise
Bridgette G J O'Malley, Robert A Robergs, Karel Hrach, et al.
Annals of Plastic Surgery
|
June 2, 2011
Outcome study of the surgical management of panniculitis
John Zannis, Benjamin C Wood, Leah P Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 1999
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models
M G Rosenblum, L K Shawver, J W Marks, et al.
Cancer Research
|
November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies
Yu Cao, James D Marks, John W Marks, et al.
Oncogene
|
February 5, 2013
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies
Y Cao, J W Marks, Z Liu, et al.
The American Journal of Gastroenterology
|
February 1, 1978
Gallstone dissolution by chenodeoxycholic acid and phenobarbital
J W Marks, J H Sherman, G G Bonorris, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
June 29, 1999
The spontaneous coat color mutant white nose (wn) maps to murine chromosome 15
P W Marks, J L Bandura, D B Shieh, et al.
Gastroenterology
|
August 1, 1984
Cyclic nucleotides and glycoproteins during formation of cholesterol gallstones in prairie dogs
R A Zak, P G Frenkiel, J W Marks, et al.
Molecular Cancer Therapeutics
|
March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu
Yu Cao, Khalid A Mohamedali, John W Marks, et al.
Vaccine
|
April 4, 2022
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years
Patrick R Funk, Osman N Yogurtcu, Richard A Forshee, et al.
Page
of 25